Track: Breast Cancer

Breast Cancer

Breast cancer session will provide a comprehensive overview of the latest advancements in breast cancer research, diagnosis, and treatment. We will discuss innovations in early detection methods, including mammography, ultrasound, and emerging molecular imaging technologies. Experts will explore the role of genetic testing and personalized medicine in identifying at-risk individuals and tailoring treatment plans to improve patient outcomes.

Invasive Ductal Carcinoma (IDC):
Gain insight into the most common type of breast cancer, Invasive Ductal Carcinoma (IDC). IDC sub-sessions will cover its pathophysiology, diagnosis, staging, and the latest treatment strategies, including surgery, chemotherapy, targeted therapy, and personalized care approaches.

Invasive Lobular Carcinoma (ILC):
Learn about Invasive Lobular Carcinoma, the second most common type of breast cancer. This sub-session will cover its unique characteristics, challenges in diagnosis, and recent advancements in treatment options, emphasizing personalized approaches and strategies for improved patient outcomes.

Ductal Carcinoma In Situ (DCIS):
Gain insight into DCIS, a non-invasive breast cancer that remains confined to the ducts. DCIS sub-session will cover diagnosis, risk factors, and treatment options, emphasizing the importance of early detection and approaches to prevent progression to invasive cancer.

Inflammatory Breast Cancer (IBC):
Gain insights into the unique characteristics, diagnosis, and challenges of inflammatory breast cancer. Inflammatory Breast Cancer sub-session will explore recent research, advancements in early detection, and innovative treatment approaches to improve outcomes and address the aggressive nature of IBC.

Triple-Negative Breast Cancer (TNBC):
Explore the unique challenges of diagnosing and treating triple-negative breast cancer, known for its aggressive nature and lack of targeted therapies. TNBC sub-session will cover recent advances in treatment strategies, clinical trials, and personalized approaches to improve patient outcomes.

HER2-Positive Breast Cancer:
Explore the significance of HER2-positive breast cancer, its impact on prognosis, and advancements in targeted therapies. This sub-session will cover current treatment strategies, including HER2-targeted drugs, resistance mechanisms, and ongoing research aimed at improving patient outcomes.